Insight Molecular Diagnostics (IMDX) Cash from Financing Activities (2015 - 2026)

Insight Molecular Diagnostics has disclosed Cash from Financing Activities across 12 years of filings, most recently posting $24.7 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $24.7 million, down 13.52% year-over-year; the trailing twelve-month figure through Mar 2026 was $24.2 million (down 50.57% YoY), and the FY2025 annual result was $28.1 million, up 37.41% from the prior year.
• Cash from Financing Activities came in at $24.7 million for Q1 2026 at Insight Molecular Diagnostics, up from -$252000.0 in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $36.8 million in Q2 2022 to a low of -$528000.0 in Q3 2022.
• The 5-year median for Cash from Financing Activities is -$30000.0 (2023), against an average of $7.6 million.
• Peak annual rise in Cash from Financing Activities reached 36223.33% in 2024, while the deepest fall reached 750.0% in 2024.
• Insight Molecular Diagnostics' Cash from Financing Activities stood at -$100000.0 in 2022, then soared by 70.0% to -$30000.0 in 2023, then jumped by 36223.33% to $10.8 million in 2024, then slumped by 102.33% to -$252000.0 in 2025, then soared by 9900.79% to $24.7 million in 2026.
• The last three Cash from Financing Activities figures came in at $24.7 million (Q1 2026), -$252000.0 (Q4 2025), and -$120000.0 (Q3 2025), per Business Quant data.